NO20006027L - Anvendelse av indigoid-bisindolderivater til fremstilling av et medikament for å hemme cyclinavhengige kinaser - Google Patents
Anvendelse av indigoid-bisindolderivater til fremstilling av et medikament for å hemme cyclinavhengige kinaserInfo
- Publication number
- NO20006027L NO20006027L NO20006027A NO20006027A NO20006027L NO 20006027 L NO20006027 L NO 20006027L NO 20006027 A NO20006027 A NO 20006027A NO 20006027 A NO20006027 A NO 20006027A NO 20006027 L NO20006027 L NO 20006027L
- Authority
- NO
- Norway
- Prior art keywords
- indigoid
- medication
- preparation
- dependent kinases
- inhibit cyclin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98109845A EP0966963A1 (en) | 1998-05-29 | 1998-05-29 | Use of indigoid bisindole derivatives as CDK1 inhibitors |
| EP99105693 | 1999-03-19 | ||
| PCT/EP1999/003625 WO1999062503A2 (en) | 1998-05-29 | 1999-05-26 | Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20006027D0 NO20006027D0 (no) | 2000-11-28 |
| NO20006027L true NO20006027L (no) | 2001-01-22 |
Family
ID=26149292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006027A NO20006027L (no) | 1998-05-29 | 2000-11-28 | Anvendelse av indigoid-bisindolderivater til fremstilling av et medikament for å hemme cyclinavhengige kinaser |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1079826B1 (no) |
| JP (1) | JP2002516851A (no) |
| KR (1) | KR20010078722A (no) |
| AT (1) | ATE233560T1 (no) |
| AU (1) | AU762830B2 (no) |
| BR (1) | BR9910810A (no) |
| CA (1) | CA2333661A1 (no) |
| DE (1) | DE69905712T2 (no) |
| DK (1) | DK1079826T3 (no) |
| ES (1) | ES2194468T3 (no) |
| HU (1) | HUP0102240A3 (no) |
| IL (1) | IL139914A0 (no) |
| NO (1) | NO20006027L (no) |
| WO (1) | WO1999062503A2 (no) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| US6624171B1 (en) | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
| PL351261A1 (en) | 1999-04-12 | 2003-04-07 | Gerhard Eisenbrand | Derivatives of indigoid bisindoles |
| EP1218004B1 (en) | 1999-04-12 | 2009-04-08 | Heinz Herbert Fiebig | 5-methyl indirubin for use in the treatment of human solid tumors |
| AU2002213132A1 (en) * | 2000-10-10 | 2002-04-22 | Board Of Regents, The University Of Texas System | Suppression of cyclin kinase activity for prevention and treatment of infections |
| DE10053474A1 (de) * | 2000-10-24 | 2002-05-02 | Schering Ag | Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung |
| DE10061162A1 (de) * | 2000-11-30 | 2002-07-11 | Schering Ag | Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung |
| WO2002059123A2 (en) * | 2000-12-18 | 2002-08-01 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds |
| FR2821358B1 (fr) * | 2001-02-27 | 2006-04-07 | Aventis Pharma Sa | Oxindoles inhibiteurs de cdk-1 et leur application en therapeutique |
| DE10114138C2 (de) * | 2001-03-16 | 2003-03-27 | Schering Ag | Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit |
| DE10125763A1 (de) * | 2001-05-17 | 2002-11-28 | Schering Ag | Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren |
| DE10129028A1 (de) * | 2001-06-11 | 2003-01-02 | Schering Ag | Lösliche Cdk-inhibitorische Indirubinderivate |
| TW201041580A (en) * | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| US7582670B2 (en) | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
| US6566341B1 (en) * | 2001-12-13 | 2003-05-20 | Natrogen Therapeutics, Inc. | Derivative of isoindigo, indigo and indirubin for the treatment of cancer |
| US20050154046A1 (en) | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| JP2005516938A (ja) * | 2001-12-13 | 2005-06-09 | ナトロジェン・セラピューティクス・インコーポレーテッド | イソインジゴ、インジゴおよびインジルビンの誘導体、ならびに癌治療における使用 |
| US8563525B2 (en) | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
| AU2003228427B2 (en) * | 2002-04-03 | 2009-07-02 | Allergan, Inc. | (3Z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors |
| CN1199946C (zh) * | 2002-10-29 | 2005-05-04 | 无锡杰西医药科技有限公司 | 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用 |
| KR100588803B1 (ko) * | 2004-01-27 | 2006-06-12 | 학교법인조선대학교 | 암세포주에 항암활성을 지닌 인디루빈 유도체 |
| CA2566396A1 (en) * | 2004-05-12 | 2005-11-17 | Bayer Cropscience Gmbh | Plant growth regulation |
| MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| CN1329376C (zh) * | 2005-09-19 | 2007-08-01 | 无锡杰西医药科技有限公司 | 一种n（1）－烃基－3′－肟基靛玉红衍生物（i）的制备方法及其医学应用 |
| JP4587961B2 (ja) * | 2006-01-16 | 2010-11-24 | 独立行政法人科学技術振興機構 | 神経因性疼痛治療剤 |
| EP2379549B1 (en) | 2008-12-22 | 2016-09-21 | Eisenbrand, Gerhard | 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament |
| EP2199292A1 (en) | 2008-12-22 | 2010-06-23 | Technische Universität Kaiserlautern | 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament |
| FR2945747A1 (fr) | 2009-05-25 | 2010-11-26 | Centre Nat Rech Scient | Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire |
| FR2952818B1 (fr) * | 2009-11-23 | 2013-05-31 | Oreal | Composition contenant au moins un precurseur de coloration derive d'indole, au moins un colorant indoline dione et au moins un compose organique liquide |
| KR101180030B1 (ko) * | 2010-02-05 | 2012-09-05 | 광주과학기술원 | 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체 |
| US8524121B2 (en) * | 2012-01-27 | 2013-09-03 | Xerox Corporation | Bi-indoline-dithione polymers |
| WO2013142817A2 (en) | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| CN103333161B (zh) * | 2013-05-28 | 2015-09-30 | 滁州市洛达生物科技有限公司 | 1’-氧代靛玉红的制备和用途 |
| US12097261B2 (en) | 2021-05-07 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
| CN113773243B (zh) * | 2021-09-01 | 2023-01-06 | 大连理工大学 | 一种有机催化氧化吲哚自缩合制备异靛蓝类化合物的方法 |
| MX2024004264A (es) | 2021-10-08 | 2024-07-10 | Azora Therapeutics Inc | Derivados de agonistas de los receptores de aril hidrocarburos. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS617254A (ja) * | 1984-06-20 | 1986-01-13 | Isukura Sangyo Kk | ビスインドリノンおよびそれを主成分とする制癌剤 |
| AU4155697A (en) * | 1996-08-23 | 1998-03-06 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
-
1999
- 1999-05-26 KR KR1020007013499A patent/KR20010078722A/ko not_active Application Discontinuation
- 1999-05-26 EP EP99926420A patent/EP1079826B1/en not_active Expired - Lifetime
- 1999-05-26 DK DK99926420T patent/DK1079826T3/da active
- 1999-05-26 BR BR9910810-0A patent/BR9910810A/pt not_active IP Right Cessation
- 1999-05-26 JP JP2000551759A patent/JP2002516851A/ja active Pending
- 1999-05-26 IL IL13991499A patent/IL139914A0/xx unknown
- 1999-05-26 CA CA002333661A patent/CA2333661A1/en not_active Abandoned
- 1999-05-26 HU HU0102240A patent/HUP0102240A3/hu unknown
- 1999-05-26 ES ES99926420T patent/ES2194468T3/es not_active Expired - Lifetime
- 1999-05-26 DE DE69905712T patent/DE69905712T2/de not_active Expired - Fee Related
- 1999-05-26 WO PCT/EP1999/003625 patent/WO1999062503A2/en not_active Application Discontinuation
- 1999-05-26 AU AU43687/99A patent/AU762830B2/en not_active Ceased
- 1999-05-26 AT AT99926420T patent/ATE233560T1/de not_active IP Right Cessation
-
2000
- 2000-11-28 NO NO20006027A patent/NO20006027L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU4368799A (en) | 1999-12-20 |
| JP2002516851A (ja) | 2002-06-11 |
| CA2333661A1 (en) | 1999-12-09 |
| BR9910810A (pt) | 2001-02-13 |
| ATE233560T1 (de) | 2003-03-15 |
| EP1079826B1 (en) | 2003-03-05 |
| DE69905712D1 (de) | 2003-04-10 |
| AU762830B2 (en) | 2003-07-03 |
| ES2194468T3 (es) | 2003-11-16 |
| IL139914A0 (en) | 2002-02-10 |
| HUP0102240A3 (en) | 2003-05-28 |
| WO1999062503A3 (en) | 2000-01-27 |
| WO1999062503A2 (en) | 1999-12-09 |
| KR20010078722A (ko) | 2001-08-21 |
| HUP0102240A2 (hu) | 2001-11-28 |
| DE69905712T2 (de) | 2004-01-29 |
| EP1079826A2 (en) | 2001-03-07 |
| NO20006027D0 (no) | 2000-11-28 |
| DK1079826T3 (da) | 2003-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20006027L (no) | Anvendelse av indigoid-bisindolderivater til fremstilling av et medikament for å hemme cyclinavhengige kinaser | |
| MXPA03010810A (es) | Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos. | |
| LUC00197I2 (no) | ||
| MY137888A (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| IL167086A (en) | 7- (Single-Converted Amino) -Pyrazolo [5,1-a] Pyrimidine as Cyclin-dependent Kinase Inhibitors and Pharmaceuticals Containing Them | |
| UY27592A1 (es) | Nuevo uso | |
| DE69928235D1 (de) | Cyclin-abhängige kinase inhibitoren | |
| BR0108394A (pt) | Inibidores de cinase de proteìna de 2-indolinona de pirrol substituìdo | |
| WO1999057117A3 (de) | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen | |
| CA2309551A1 (en) | Aminothiazole inhibitors of cyclin dependent kinases | |
| BR0312633A (pt) | Composto, uso do composto, composição farmacêutica, processo para a preparação de um composto | |
| ID27757A (id) | Indolinona-indolinona tersubstitusi baru, preparasi dan penggunaannya sebagai obat | |
| BR0016420A (pt) | Aminotiazóis inibidores de cinases dependentes de ciclinas | |
| BG103417A (en) | Condensed pyrimidine bicyclic derivatives | |
| AR022665A1 (es) | Compuestos farmaceuticamente activos | |
| MY138352A (en) | Benzothiazole derivatives | |
| WO2002024700A3 (en) | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | |
| GEP20032896B (en) | 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment | |
| HUP0400991A2 (hu) | Dihidro-benzo[b][1,4]diazepin-2-on-származékok, mint MGluR2 I antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0204141A2 (hu) | Pirido[2,3-d]pirimidin-2,7-diamin típusú kináz-inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| TR200101860T2 (tr) | Sikline bağlı kinaz inhibitörleri olarak 4-alkenil (ve alkinil) oksidoller | |
| SE8703169L (sv) | 1-(4-aminofenyl)-4-metyl-7,8-metylendioxi-3,4-dihydro-5h-2,3-bensodiazepin, syraadditionssalter derav samt forfarande for framstellning av densamma | |
| PL375697A1 (en) | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors | |
| PE20030236A1 (es) | Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados | |
| WO1998049146A3 (en) | Cyclin dependent kinase (cdk)4 inhibitors and their use for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |